Skip to main content
Navigate Up
Sign In

Dr. David A. Schwartz Named to NuMedii Advisory Board as IPF Expert

Earlier this week, NuMedii, Inc. announced the official formation of an Idiopathic Pulmonary Fibrosis (IPF) Advisory Board.

The newly created Board of Advisors will seek to provide deep scientific and clinical expertise to the company as it discovers and advances new treatments for IPF, based on NuMedii's Artificial Intelligence for Drug Discovery (AIDD) technology.

IPF is a progressive, life-threatening disease with poor prognosis in which the replacement of small air sacs of the lung with fibrotic tissue causes the gradual worsening of dyspnea. The condition is characterized by common symptoms like shortness of breath; fatigue; dry, hacking cough; and shallow breathing.

By partnering information from basic human biology that consists of both insights from literature and molecular, pharmacological and clinical data points with proprietary machine learning and network-based algorithms, NuMedii’s AIDD technology seeks to discover and advance precise, effective new drug candidates, and biomarkers predictive of efficacy for subsets of patients in IPF and other rare diseases.

Read more​​​​​